Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Default user image.

Carola Tilgmann

Driftchef

Default user image.

Discovery and Structural Characterization of a Phospholamban-Binding Cyclic Peptide and Design of Novel Inhibitors of Phospholamban

Författare

  • Carola Tilgmann
  • Piero Pollesello
  • Martti Ovaska
  • Juha Kaivola
  • Jarmo Pystynen
  • Eija Tiainen
  • Marjo Yliperttula
  • Arto Annila
  • Jouko Levijoki

Summary, in English

The interplay between cardiac sarcoplasmic Ca2+ATPase and phospholamban is a key regulating factor of contraction and relaxation in the cardiac muscle. In heart failure, aberrations in the inhibition of sarcoplasmic Ca2+ATPase by phospholamban are associated with anomalies in cardiac functions. In experimental heart failure models, modulation of the interaction between these two proteins has been shown to be a potential therapeutic approach. The aim of our research was to find molecules able to interfere with the inhibitory activity of phospholamban on sarcoplasmic Ca2+ATPase. For this purpose, a portion of phospholamban was synthesized and used as target for a phage-display peptide library screening. The cyclic peptide C-Y-W-E-L-E-W-L-P-C-A was found to bind to phospholamban (1-36) with high specificity. Its functional activity was tested in Ca2+uptake assays utilizing preparations from cardiac sarcoplasmic reticulum. By synthesizing and testing a series of alanine point-mutated cyclic peptides, we identified which amino acid was important for the inhibition of the phospholamban function. The structures of active and inactive alanine-mutated cyclic peptides, and of phospholamban (1-36), were determined by NMR. This structure-activity analysis allowed building a model of phospholamban -cyclic peptide complex. Thereafter, a simple pharmacophore was defined and used for the design of small molecules. Finally, examples of such molecules were synthesized and characterized as phospholamban inhibitors. Molecules able to interfere with the inhibitory activity of phospholamban (PLB) on SERCA2a were discovered. PLB was used as target for a phage display peptide library screening. The cyclic peptide C-Y-W-E-L-EW-L-P-C-A was found to bind to PLB and interfere with its activity. Its structure was determined and a model of this interaction with PLB was built. A pharmacophore was defined and used for the design of small molecules. Examples of such molecules were synthesized and characterized as phospholamban inhibitors.

Publiceringsår

2013-04

Språk

Engelska

Sidor

463-473

Publikation/Tidskrift/Serie

Chemical Biology and Drug Design

Volym

81

Issue

4

Dokumenttyp

Artikel i tidskrift

Förlag

Wiley-Blackwell

Nyckelord

  • Calcium uptake
  • Cardiac contraction-relaxation cycle
  • Cardiomyocytes
  • Drug discovery
  • Heart disease
  • Pharmacophore
  • Sarcoplasmic reticulum

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1747-0277